Last $9.02 USD
Change Today -0.80 / -8.15%
Volume 1.4M
RTRX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 5:20 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

retrophin inc (RTRX) Snapshot

Open
$9.92
Previous Close
$9.82
Day High
$10.10
Day Low
$8.86
52 Week High
04/3/14 - $24.25
52 Week Low
11/12/13 - $5.25
Market Cap
237.2M
Average Volume 10 Days
526.5K
EPS TTM
$-4.26
Shares Outstanding
26.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RETROPHIN INC (RTRX)

retrophin inc (RTRX) Related Bloomberg News

View More Bloomberg News

retrophin inc (RTRX) Details

Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases. It sells Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; and Vecamyl for the treatment of hypertension. The company develops Syntocinon Nasal Spray, an oxytocin nasal spray product for aiding milk let-down, as well as for the treatment of schizophrenia and autism; and RE-034, a synthetic hormone analogue that is composed of the first 24 amino acids of the 39 amino acids contained in the naturally occurring adrenocorticotrophic hormone for the treatment of infantile spasms and nephrotic syndrome. It also develops RE-024, a novel small molecule for the treatment of pantothenate kinase associated neurodegeneration; Sparsentan, a dual acting receptor antagonist of angiotensin and endothelin receptors for the treatment of focal segmental glomerulosclerosis; and RE-001, a therapy for the treatment of duchenne muscular dystrophy. In addition, the company intends to obtain FDA approval of Chenodal for the treatment of cerebrotendinous xanthomatosis; and for the treatment of patients with biliary cirrhosis. Retrophin, Inc. is based in New York, New York.

26 Employees
Last Reported Date: 03/28/14

retrophin inc (RTRX) Top Compensated Officers

Founder, Chief Executive Officer and Director
Total Annual Compensation: $1.5M
Chairman, President and Chief Operations Offi...
Total Annual Compensation: --
Chief Financial Officer and Chief Accounting ...
Total Annual Compensation: $246.3K
Chief Medical Officer
Total Annual Compensation: $359.4K
Compensation as of Fiscal Year 2013.

retrophin inc (RTRX) Key Developments

Retrophin, Inc. Announces Changes to Board of Directors and Management Team

Retrophin, Inc. announced that Jeffrey Paley, MD has stepped down as a member of the Board of Directors and Marc Panoff has decided to leave his role as Chief Financial Officer (CFO). Mr. Panoff will continue overseeing financial operations until a CFO replacement is in place.

Retrophin Mulls Acquisitions

Retrophin, Inc. (NasdaqGM:RTRX) is seeking acquisitions. Retrophin, Inc. has filed a shelf registration and intends to use the proceeds for expanding existing businesses, acquiring businesses or investing in other business opportunities among other uses.

Retrophin, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Reiterates Revenue Guidance for 2014; Reiterates Earnings Guidance for 2015

Retrophin, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. Non-GAAP net loss for the second quarter of 2014 was $13.3 million, or $0.52 per basic and diluted share, compared to $2.6 million, or $0.21 per basic and diluted share, for the second quarter of 2013. GAAP net income for the second quarter of 2014 was $8.5 million, or $0.33 per basic share and a $0.90 net loss per dilutive share, compared to a net loss of $5.0 million, or $0.41 per diluted share, for the second quarter of 2013. Net income for the second quarter of 2014 included income of $33.0 million related to the change in fair value of the Company's derivative instruments, as well as an income tax benefit of $2.5 million. Net product sales were $5,741,734 for the quarter. Operating loss was $20,503,723 against $5,099,902 a year ago. Income before provision for income taxes was $5,957,823 against loss of $5,048,513 a year ago. On non-GAAP basis, operating loss was $13,706,902 against $2,573,951 a year ago. Non-GAAP loss before provision for income taxes was $13,336,725 against $2,578,603 a year ago. For the six months, net product sales were $5,769,634. Operating loss was $37,455,471 against $7,350,386 a year ago. Loss before provision for income taxes was $64,602,527 against $9,791,435 a year ago. Net loss was $62,142,779 or $2.54 per diluted share against $9,791,435 or $0.85 per diluted share a year ago. Non-GAAP adjusted net loss was $24,240,628 or $0.99 per diluted share against $4,501,935 or $0.39 per diluted share a year ago. On non-GAAP basis, operating loss was $24,615,469 against $4,498,062 a year ago. Non-GAAP loss before provision for income taxes was $24,240,628 against $4,501,935 a year ago. For the year 2014, the company expects revenue of $30 million to $35 million. For the year 2015, the company expects revenue of $60 million to $70 million and EPS (non-GAAP) of $0.75 to $1.25.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RTRX:US $9.02 USD -0.80

RTRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RTRX.
View Industry Companies
 

Industry Analysis

RTRX

Industry Average

Valuation RTRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 43.6x
Price/Book 242.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RETROPHIN INC, please visit www.retrophin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.